Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: It is important to understand the impact of the COVID-19 pandemic on cancer death rates in 2020 in the US. We estimated whether there were larger-than-expected changes in cancer mortality rates from March to December 2020 after accounting for temporal and seasonal patterns using data from January 2011 to February 2020 by cancer type and age.

Methods: We obtained death counts and underlying causes of death by cancer type, month/year (2011-2020), and age group from the National Center for Health Statistics and population estimates from the US Census Bureau. Poisson regression was used to test for significant changes in cancer death rates from March to December 2020 compared with prior years.

Results: After accounting for temporal trends and seasonal patterns, total cancer death rates were significantly lower than expected during March to December 2020 among 55- to 64-year-olds and ≥75-year-olds, but not in other age groups. Cancer death rates were 2% lower than expected from March to June among 55- to 64-year-olds and 2% to 3% lower from March to July and December among ≥75-year-olds. Among ≥75-year-olds, colorectal cancer death rates were lower from March to June [rate ratios (RR) = 0.94-0.96; P < 0.05]; however, lung cancer death rates were 5% lower across each month (all RRs = 0.95; P < 0.05).

Conclusions: In the US, cancer death rates based on the underlying cause of death were broadly similar to expected rates from March to December 2020. However, cancer death rates were lower than expected among 55- to 64-year-olds and ≥75-year-olds, likely due to COVID-19 as a competing cause of death.

Impact: Cancer mortality rates from 2020 should be interpreted with caution.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11293979PMC
http://dx.doi.org/10.1158/1055-9965.EPI-24-0121DOI Listing

Publication Analysis

Top Keywords

cancer death
32
death rates
32
march december
20
december 2020
20
rates lower
20
cancer mortality
12
cancer
12
rates march
12
lower expected
12
55- 64-year-olds
12

Similar Publications

Importance: Black individuals have a twofold higher rate of prostate cancer death in the US compared with the average population with prostate cancer. Few guidelines support race-conscious screening practices among at-risk Black individuals.

Objective: To examine structural factors that facilitate or impede access to prostate cancer screening among Black individuals in the US.

View Article and Find Full Text PDF

Despite significant advancements in the treatment of non-small cell lung cancer (NSCLC) using conventional therapeutic methods, drug resistance remains a major factor contributing to disease recurrence. In this study, we aimed to explore the potential benefits of combining PI3K inhibition with Cisplatin in the context of NSCLC-derived A549 cells. Human non-small cell lung cancer A549 cells were cultured and treated with BKM120, cisplatin, or their combination.

View Article and Find Full Text PDF

Expression analysis of C-FOS and XRCC3 Thr241Met polymorphism in gastric cancer.

Cell Mol Biol (Noisy-le-grand)

September 2025

Department of Biology, College of Education for Pure Sciences, University of Kerbala, Kerbala, Iraq.

Gastric cancer is one of the causes of deaths related to cancer across the globe and both genetic and environmental factors are the most prominent. Causes of its pathogenesis. This paper researches the expression of the C-FOS gene.

View Article and Find Full Text PDF

Background: Standard treatment for glioblastoma includes chemotherapy, alkylating agents such as temozolomide (TMZ); however, MGMT resistance leads to recurrence. Demethoxycurcumin (DMC) has been reported to inhibit cancer cell growth, induce apoptosis, and prevent metastasis in different cancer models. We investigated the DMC-induced apoptosis and autophagy via inhibition of the AKT/mTOR pathway in human glioma U87MG and T98G cell lines.

View Article and Find Full Text PDF

Introduction: Trastuzumab emtansine (T-DM1), an antibody-drug conjugate, targets tumor cells overexpressing human epidermal growth factor receptor 2 (HER2). This single-arm, phase IV study assessed the safety and efficacy of T-DM1 in Indian patients with HER2-positive, locally advanced, or metastatic breast cancer previously treated with trastuzumab and a taxane.

Methods: Patients received T-DM1 (3.

View Article and Find Full Text PDF